# Biotech Alpha Trading Report
**Generated**: January 3, 2026
**Analysis Period**: Next 90 Days (Jan 3 - Apr 3, 2026)
**Strategy**: PDUFA Run-up (D-60 Entry, D-7 Exit)

---

## Executive Summary

**Objective**: Identify biotech stocks with FDA PDUFA events where the "anticipation run-up" entry window (Event - 60 days) falls within the next 90 days.

**Results**: **4 verified opportunities** identified from initial scan of 14+ events. All recommendations have confirmed PDUFA dates from official company IR sources and pass financial risk screening.

**Top Picks**:
1. **REPL** (Replimune Group) - Strong Buy | Entry: Feb 9 | PDUFA: Apr 10
2. **AXSM** (Axsome Therapeutics) - Buy | Entry: Feb 29 | PDUFA: Apr 30
3. **RYTM** (Rhythm Pharmaceuticals) - Hold/Buy | Entry: Jan 19 | PDUFA: Mar 20
4. **ALDX** (Aldeyra Therapeutics) - Speculative Buy | Entry: Jan 15 | PDUFA: Mar 16

---

## Detailed Analysis

### 1. REPL - Replimune Group Inc. ðŸŸ¢ STRONG BUY

**Drug**: RP1 + nivolumab (oncolytic immunotherapy for advanced melanoma)
**PDUFA Date**: April 10, 2026 (Priority BLA, Class II Resubmission)
**Current Price**: $9.14 | **Entry Window**: Feb 9, 2026 | **Exit Window**: Apr 3, 2026

#### Why This Works
- **Perfect Timing**: Entry date is 37 days away - ideal positioning for accumulation
- **Strong Catalyst**: FDA accepted BLA resubmission (Oct 2025) after addressing CRL issues
- **Momentum**: Stock up 86.51% in past month on BLA acceptance news
- **Financial Strength**: $536.5M cash, 20-month runway - zero dilution risk
- **Technical**: Price consolidating after spike, good entry setup

#### Risk Assessment
- **Risk Level**: LOW
- **Runway**: Q4 2026 (ample time through PDUFA)
- **Binary Risk**: Mitigated by exiting 7 days before decision

**Action**: Accumulate between $8.50-$9.50 starting Feb 9. Target exit Apr 3.

---

### 2. AXSM - Axsome Therapeutics Inc. ðŸŸ¢ BUY

**Drug**: AXS-05 (Alzheimer's disease agitation)
**PDUFA Date**: April 30, 2026 (Priority Review, Breakthrough Therapy Designation)
**Current Price**: $152.05 | **Entry Window**: Feb 29, 2026 | **Exit Window**: Apr 23, 2026

#### Why This Works
- **De-risked Play**: AXS-05 already approved as Auvelity for MDD ($500M+ annualized sales)
- **Huge Market**: AD agitation is $3B peak sales opportunity (Truist estimate)
- **Priority Review**: 6-month review cycle indicates FDA urgency
- **Near Profitability**: Revenue growing 63% YoY, approaching cash flow positive
- **Strong Balance Sheet**: $325M cash, no financing needs

#### Risk Assessment
- **Risk Level**: LOW
- **Runway**: Approaching profitability (infinite runway)
- **Approval Probability**: Higher than typical due to existing MDD approval and Breakthrough designation

**Action**: Accumulate on dips starting late Feb. Exit Apr 23 regardless of sentiment.

---

### 3. RYTM - Rhythm Pharmaceuticals Inc. ðŸŸ¡ HOLD/BUY

**Drug**: Imcivree (acquired hypothalamic obesity sNDA)
**PDUFA Date**: March 20, 2026 (Priority Review, extended from Dec 2025)
**Current Price**: $112.14 | **Entry Window**: Jan 19, 2026 | **Exit Window**: Mar 13, 2026

#### Why This Works
- **Imminent Entry**: Entry window opens in 16 days (Jan 19)
- **Revenue-Stage Asset**: IMCIVREE already approved for age 12+ rare obesity disorders
- **Strong Financials**: $416M cash, 24-month runway, $51M Q3 revenue (+54% YoY)
- **Orphan Status**: Rare disease designation reduces competitive risk
- **Analyst Support**: Strong Buy consensus, $127 avg PT vs $112 current

#### Risk Assessment
- **Risk Level**: LOW
- **Runway**: 24 months (exceptional)
- **Timing Risk**: Entry window approaching fast - monitor closely

**Action**: Watch for entry setup Jan 15-19. If entering, plan exit by Mar 13 (7 days before PDUFA).

---

### 4. ALDX - Aldeyra Therapeutics Inc. ðŸ”´ SPECULATIVE BUY

**Drug**: Reproxalap (dry eye disease)
**PDUFA Date**: March 16, 2026 (Standard NDA, 3rd submission)
**Current Price**: $4.72 | **Entry Window**: Jan 15, 2026 | **Exit Window**: Mar 9, 2026

#### Why This Works
- **Deep Value**: Trading near 52-week low ($1.14-$7.20 range)
- **Positive Signal**: FDA provided draft label in Dec 2025 (suggests approval leaning)
- **Analyst Upside**: $7-13 price targets vs $4.72 current (48-176% upside)
- **Entry Timing**: Entry window opens in 12 days (Jan 15)

#### Why This Is Risky
- **2 Prior CRLs**: FDA rejected twice (2023, 2024) on efficacy concerns
- **Limited Runway**: 12 months cash (~$75M) - may need financing mid-2026
- **Market Skepticism**: Stock priced for failure despite draft label
- **Small Cap**: $283M market cap = high volatility

#### Risk Assessment
- **Risk Level**: MEDIUM-HIGH
- **Runway**: 12 months (adequate through PDUFA, tight after)
- **Binary Risk**: Highest of all 4 picks - true binary bet

**Action**: ONLY for risk-tolerant traders. Small position size. Enter Jan 15-20, strict exit Mar 9.

---

## Events EXCLUDED & Why

### CING - Cingulate Inc. âŒ REJECTED
- **PDUFA**: May 31, 2026 (CTx-1301 ADHD)
- **Rejection Reason**: **CRITICAL CASH RISK**
  - Only $6.1M cash vs $7M quarterly burn
  - Runway to Q2 2026 only
  - Needs $7M raise before PDUFA
  - High dilution risk = violates strategy rules

### CYTK - Cytokinetics âŒ NO PDUFA
- April 30, 2026 date unverified
- Omecamtiv mecarbil received CRL in 2023
- No active NDA under review

### LENZ Therapeutics âŒ ALREADY APPROVED
- VIZZ approved July 2025 (ahead of Aug 2025 PDUFA)
- No upcoming catalysts

### CORT - Corcept Therapeutics âŒ JUST REJECTED
- Relacorilant received CRL Dec 31, 2025
- Stock down 50%
- No immediate re-filing catalyst

---

## Trading Strategy & Risk Management

### Entry Rules
1. **Timing**: Enter during "Entry Window" (D-60 to D-45)
2. **Position Sizing**:
   - Strong Buy (REPL, AXSM): Up to 5% portfolio each
   - Hold/Buy (RYTM): 3-4% portfolio
   - Speculative (ALDX): Max 2% portfolio
3. **Scaling**: Accumulate over 3-5 days, not all at once

### Exit Rules (NON-NEGOTIABLE)
- **Exit ALL positions by D-7** (7 days before PDUFA)
- **DO NOT hold through binary event**
- Example exits:
  - REPL: Exit by April 3 (PDUFA Apr 10)
  - AXSM: Exit by April 23 (PDUFA Apr 30)
  - RYTM: Exit by March 13 (PDUFA Mar 20)
  - ALDX: Exit by March 9 (PDUFA Mar 16)

### Stop-Loss Guidelines
- **Pre-Entry**: If stock runs >15% before entry window, skip
- **Post-Entry**: -15% stop from entry price OR exit at D-7, whichever comes first
- **Priority**: Always exit by D-7 regardless of P&L

---

## Market Calendar

| Date | Event | Ticker | Action |
|------|-------|--------|--------|
| **Jan 15** | Entry window opens | ALDX | Start accumulation (speculative) |
| **Jan 19** | Entry window opens | RYTM | Start accumulation (if buying) |
| **Feb 9** | Entry window opens | REPL | Start accumulation (strong buy) |
| **Feb 29** | Entry window opens | AXSM | Start accumulation (buy) |
| **Mar 9** | MANDATORY EXIT | ALDX | Sell all positions |
| **Mar 13** | MANDATORY EXIT | RYTM | Sell all positions |
| **Mar 16** | PDUFA Decision | ALDX | Do NOT hold |
| **Mar 20** | PDUFA Decision | RYTM | Do NOT hold |
| **Apr 3** | MANDATORY EXIT | REPL | Sell all positions |
| **Apr 10** | PDUFA Decision | REPL | Do NOT hold |
| **Apr 23** | MANDATORY EXIT | AXSM | Sell all positions |
| **Apr 30** | PDUFA Decision | AXSM | Do NOT hold |

---

## Key Assumptions & Disclaimers

### Strategy Logic
- **Historical Pattern**: Biotech stocks often see 20-40% run-up in the 60 days before major FDA decisions as speculation increases
- **Exit Rationale**: Binary events (approval/rejection) are coin flips - exit during hype phase, not speculation aftermath
- **Risk Control**: Cash runway <6 months = automatic exclusion (dilution destroys run-up gains)

### Verification Standards
- All PDUFA dates verified via official company IR press releases
- Third-party calendar sites (BioPharmCatalyst, CatalystAlert) used for discovery only, NOT confirmation
- Cash positions sourced from Q3 2025 10-Q filings or earnings releases

### Limitations
- This is NOT investment advice - for informational purposes only
- PDUFA dates can be extended by FDA (monitor company updates)
- Market conditions, competitor news, or macro events can override technical patterns
- Past run-up patterns do not guarantee future performance

---

## Data Sources

### Event Discovery
- [CatalystAlert PDUFA Calendar](https://catalystalert.io)
- [BioPharmCatalyst FDA Calendar](https://www.biopharmcatalyst.com)

### Official Verification
- [Aldeyra IR](https://ir.aldeyra.com)
- [Rhythm Pharmaceuticals IR](https://ir.rhythmtx.com)
- [Replimune IR](https://ir.replimune.com)
- [Axsome Therapeutics Newsroom](https://www.globenewswire.com)

### Financial Data
- Company 10-Q filings (Q3 2025)
- Earnings call transcripts (Nov 2025)
- Yahoo Finance, Investing.com (price data)

---

## Next Steps

1. **Monitor Entry Windows**: Set alerts for Jan 15 (ALDX), Jan 19 (RYTM), Feb 9 (REPL), Feb 29 (AXSM)
2. **Track FDA Updates**: Subscribe to company IR email alerts for PDUFA date changes
3. **Watch Technical Setups**: Don't chase - wait for consolidation or pullbacks during entry windows
4. **Set Exit Reminders**: Non-negotiable exits 7 days before each PDUFA date

---

**Report Generated by**: Biotech Alpha CIO Agent
**Methodology**: Hierarchical Multi-Agent System (Discovery â†’ Verification â†’ Quant â†’ Risk â†’ Analysis)
**Version**: 1.0 | **Date**: 2026-01-03
